Powder: -20°C for 3 years | In solvent: -80°C for 1 year
SC-560 is a member of the diaryl heterocycle class of cyclooxygenase (COX) inhibitors.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
2 mg | In stock | $ 33.00 | |
5 mg | In stock | $ 52.00 | |
10 mg | In stock | $ 93.00 | |
25 mg | In stock | $ 198.00 | |
50 mg | In stock | $ 252.00 | |
100 mg | In stock | $ 323.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 58.00 |
Description | SC-560 is a member of the diaryl heterocycle class of cyclooxygenase (COX) inhibitors. |
Targets&IC50 | COX-1:9 nM. |
In vitro | Preincubation of cyclooxygenase-1 (COX-1) with SC-560 selectively inhibits the conversion of arachidonic acid to prostaglandin E2 (PGE2) in a concentration-dependent manner, demonstrating higher specificity for COX-1 over COX-2, as indicated by SC-560's inhibitory concentration 50 (IC50) for COX-2 being 6.3 μM, nearly 1,000-fold greater than for COX-1. Furthermore, SC-560 has been shown to suppress hepatocellular carcinoma (HCC) cell growth, colony formation in soft agar, and induce apoptosis in a dose- and time-dependent manner. Additionally, it downregulates anti-apoptotic proteins, including survivin and X-linked inhibitor of apoptosis protein (XIAP), while simultaneously activating caspases 3 and 7, illustrating its therapeutic potential in HCC treatment through multifaceted mechanisms of action. |
In vivo | Oral dosing with either 10 or 30 mg/kg SC-560 1 hour before assay completely inhibits ionophore-stimulated TxB2production, indicating that SC-560 is orally bioavailable and inhibits COX-1 in vivo. SC-560 extensively distributes into rat tissues, and has a CL approaching hepatic plasma flow. After oral administration, the drug exhibits low less than 15% formulation-dependent bioavailability and demonstrates kidney toxicity. |
Kinase Assay | Test compound is incubated with human whole blood stimulated with bacterial LPS for 4 h, followed by capture of MPO on immobilized anti-MPO antibody coated plates. The captured MPO is washed and residual MPO activity is determined using Amplex Red and H2O2. |
Cell Research | SC-560 is dissolved in DMSO[2].HuH-6 and HA22T/VGH cells (5000/well) are treated with various concentrations of SC-560 (5, 10, 25, 50, 100, 200 μM) and cultured for 72 h. At the end of treatment, cell viability is assessed by MTS assay. |
Animal Research | Rat: The pharmacokinetics of SC-560 is studied in Sprague-Dawley rats after a single intravenous (i.v.) and oral dose (10 mg/kg) in polyethylene glycol (PEG) 600 and a single oral dose (10 mg/kg) in 1% methylcellulose (MC). Serial blood samples are collected via a catheter inserted in the right jugular vein and serum samples are analysed for SC-560 using reverse phase HPLC. After oral administration of SC-560 in PEG, urine is also collected for 24 h and analyzed for urinary sodium, chloride, and potassium as well as NAG. |
Synonyms | SC560 |
Molecular Weight | 352.74 |
Formula | C17H12ClF3N2O |
CAS No. | 188817-13-2 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 35.3 mg/mL(100 mM)
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
SC-560 188817-13-2 Immunology/Inflammation Neuroscience COX Cyclooxygenase inhibit SC 560 Inhibitor SC560 inhibitor